Psoriatic Arthritis Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The psoriatic arthritis therapeutics market addresses an autoimmune inflammatory condition characterized by joint pain, swelling, and skin psoriasis symptoms. With a current global valuation of approximately $34.1 billion in 2025, the market demonstrates strong momentum fueled by effective biologic and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). The condition's close therapeutic overlap with plaque psoriasis, where many treatments are shared across both indications, creates economies of scale that benefit drug development and market expansion.

• •Psoriatic arthritis affects approximately 1.0 million diagnosed adults in the US, representing about 1.4% of the national arthritis population
• •The broader psoriasis therapy market reached $31.61 billion in 2024 and is projected to expand at an 8% compound annual growth rate through 2034
• •The global monoclonal antibody market, which encompasses key psoriatic arthritis biologics, is projected to reach $494.44 billion by 2030

Several interconnected factors are accelerating market expansion, including rising global prevalence of autoimmune disorders, improved diagnostic capabilities, and growing physician awareness of long-term disease complications from undertreated psoriatic arthritis. The biologics segment has demonstrated particularly strong performance, growing at a 10% annual rate from 2014 through 2024, significantly outpacing traditional pharmaceutical market growth baselines of 5.5% to 6.2%. Expanding insurance coverage for specialty medications and the introduction of biosimilar alternatives are also enhancing patient access to previously cost-prohibitive therapies.

• •Biologics market for autoimmune conditions grew at 10% CAGR from 2014 to 2024, directly impacting anti-inflammatory treatment demand and cost dynamics
• •Specialty pharmaceutical segments, particularly biologics, are expanding at double the baseline pharmaceutical market growth rate of 5.5%-6.2% projected through 2030
• •Global biologic and biosimilar sales are projected to reach $75 billion by 2030, with psoriatic arthritis and psoriasis treatments contributing substantial revenue share

The market is segmented by drug class, with biologics, particularly anti-TNF inhibitors and IL-12/23 and IL-23 inhibitors, dominating current treatment paradigms, while small-molecule targeted therapies represent an expanding segment. Geographically, North America and Europe currently account for the largest market shares due to higher diagnosis rates, established healthcare infrastructure, and favorable reimbursement environments for specialty medications. Emerging markets in Asia-Pacific and Latin America are experiencing accelerated growth as healthcare access improves and biologic adoption increases.

• •Biologics and biosimilars for rheumatoid and psoriatic arthritis track overlapping market trajectories, with anti-TNF therapies remaining foundational treatment options
• •The global psoriasis therapy market's 8% projected CAGR through 2034 indicates sustained expansion across both developed and emerging geographic regions
• •Pharmaceutical market meta-analyses demonstrate specialty segments like biologics consistently outperforming baseline pharmaceutical growth rates through 2030

What are the recent trends and outlook?

The market is positioned for sustained double-digit growth through the remainder of the decade, driven by pipeline innovations in oral small-molecule therapies and next-generation biologics with improved safety profiles and dosing convenience. The convergence of biosimilar availability and patent expirations for key reference products will create both pricing pressure and expanded access, particularly in cost-sensitive healthcare systems. Personalized medicine approaches, including biomarker-guided therapy selection, represent an emerging paradigm that could reshape treatment algorithms and competitive positioning among manufacturers.

• •Novel small-molecule treatments and emerging biological therapies for psoriasis and psoriatic arthritis continue advancing through clinical development, promising expanded therapeutic options
• •Biosimilar adoption is projected to accelerate significantly, with global biologic and biosimilar sales reaching $75 billion by 2030 according to IQVIA projections
• •The market's 8.0% CAGR positions it well above baseline pharmaceutical growth, reflecting strong underlying demand dynamics and therapeutic innovation momentum